Search results
FDA Advisers Overwhelmingly Oppose Approval of MDMA As a Psychotherapeutic Catalyst
Reason.com via Yahoo News· 3 days agoMAPS Efforts to make MDMA legally available as a psychotherapeutic catalyst hit a daunting roadblock...
FDA rescinds 2022 Juul ban, company to pursue marketing authorization By Investing.com
Investing.com· 2 days agoThe Food and Drug Administration (FDA) rescinded its June 2022 ban on Juul Labs’s e-cigarettes....
FDA panel recommends new COVID-19 vaccine formula for fall
UPI· 2 days agoDr. Peter Marks, who oversees the FDA's vaccine division, urged the committee to consider...
Explainer: what will the FDA’s food division restructure achieve?
Just Food via Yahoo Finance· 2 days agoLast week, the US Food and Drug Administration (FDA) released details regarding plans to modernise...
FDA rolls back Juul marketing ban, reopening possibility of authorization
CBS News· 2 days agoThe marketing denial orders were effectively paused by the agency not long after they were issued,...
FDA Approves Moderna’s mRESVIA Vaccine | JD Supra
JD Supra· 1 day agoOn May 31, 2024, Moderna announced that the FDA has approved its respiratory syncytial virus vaccine (“RSV”), mRESVIA (mRNA-1345). The vaccine...
FDA Panel to Consider Updating COVID-19 Jabs for New Virus Strains
Zacks via Yahoo Finance· 4 days agoAn FDA panel meeting is scheduled on Jun 5 to consider if COVID-19 vaccines should be updated to...
FDA rescinds marketing ban on Juul vaping products
KEYT 3 Santa Barbara· 2 days agoJuul said Thursday its products will remain on the market during scientific review. On Thursday, the FDA said court decisions since then “establish new...
FDA reverses order taking Juul vaping products off the market in US
ABC7 New York· 2 days agoThe reversal comes nearly two years after the federal health agency ordered the company's...
FDA Rescinds Juul Ban, Opening Door for Federal Clearance
The Wall Street Journal· 2 days agoThe agency hasn’t yet reached a final determination on whether they can stay on the U.S. market, but...